New Potential Therapeutic Target For Alzheimer’s Disease: Beta-CTF

New Potential Therapeutic Target For Alzheimer’s Disease: Beta-CTF
Researchers at New York University Langone Medical Center and the Nathan S. Kline Institute for Psychiatric Research (NKI) in New York recently discovered a potential therapeutic target for Alzheimer’s disease and provided more insight into the associated endosome dysfunction. The study was published in the journal Molecular Psychiatry and is entitled “Evidence that the rab5 effector APPL1 mediates APP-βCTF-induced dysfunction of endosomes in Down syndrome and Alzheimer’s disease”. Alzheimer’s disease is a neurodegenerative disorder characterized by cognitive and behavioral problems. Patients initially experience memory loss and confusion that gradually leads to behavior and personality changes, a decline in cognitive abilities and ultimately to severe loss of mental function. Alzheimer’s disease is characterized by the formation of amyloid plaques in the brain [aggregates of beta-amyloid proteins derived from the beta-amyloid precursor protein (APP)], and the loss of neurons responsible for memory and learning. Alzheimer's disease is estimated to affect more than 36 million individuals worldwide, and is the most common form of dementia in the elderly population. Currently there are no drugs available to either stop or stabilize disease progression. Endosomes are membrane-bounded compartments inside cells that sort the destiny of molecules, including degradation and recycling. Endosomes are highly active APP processing sites, where AP
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *